alfuzosin has been researched along with Sex Disorders in 12 studies
alfuzosin: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy and safety of the selective alpha(1)-blocker alfuzosin in men with lower urinary tract symptoms (LUTS) and painful ejaculation, compared with those with LUTS only, as painful ejaculation is one of the most prevalent, differentiating and bothersome symptoms in men with chronic prostatitis/chronic pelvic pain syndrome." | 9.12 | The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation. ( Elhilali, M; Emberton, M; Nickel, JC; Vallancien, G, 2006) |
| "To examine the efficacy and safety of a once-daily formulation of alfuzosin in a pooled analysis of three parallel, randomized, double-blind, placebo-controlled 3-month studies of patients with lower urinary tract symptoms (LUTS) consistent with clinical benign prostatic hyperplasia." | 9.10 | Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. ( Nordling, J; Roehrborn, CG; Van Kerrebroeck, P, 2003) |
| " Search terms included benign prostatic hyperplasia, alfuzosin, treatment, alpha(1)-adrenergic receptor blocker, long-term, followup, lower urinary tract symptoms, complications or adverse events, sexual, retention and cardiovascular." | 8.83 | Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. ( McVary, KT, 2006) |
| "To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) >8 (range of scores, 0-35), and sexual attempts at least once per month were enrolled." | 7.78 | Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia. ( Chang, HC; Chen, CS; Chen, WH; Chiang, PH; Chu, SH; Hwang, TI; Lee, LM; Lin, MS; Yeh, SD, 2012) |
| "To assess the 3-year efficacy and safety of the selective alpha(1)-blocker alfuzosin at 10 mg once daily in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in 'real-life practice'." | 7.74 | Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ, 2008) |
| " The follow-up included 3 visits: visit of inclusion in the program of patients with a previously prescribed drug of Alfuprost MR in a dosage of 10 mg once a day (visit "0"), visit 1 at 30 days (+/-5 days) later, and visit 2 at 90 days (+/-5 days) after inclusion in the study." | 5.72 | [The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)]. ( Bernikov, AN; Loran, OB; Pushkar, DY, 2022) |
| "Incidence of benign prostatic hyperplasia (BPH), one of the most common conditions affecting adult men, increases dramatically after the age of 50." | 5.42 | [Impact of alfuzosin 10 mg once daily on quality of life in Tunisian patients with lower urinary symptoms suggestive of benign prostatic hyperplasia]. ( Adbi, H; Ben Raies, N; Ben Rhouma, S; Binous, MY; H'sairi, M; Horchani, A; Mosbah, AT; Nouira, Y, 2015) |
| "To determine the effect of alfuzosin on sexual function by using the Male Sexual Health Questionnaire (MSHQ) in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)." | 5.14 | An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia. ( Cheon, J; Chung, BH; Chung, MK; Kim, MK; Kim, SW; Lee, JY; Lee, KS; Lee, SW; Park, JK; Park, K, 2010) |
| "To determine the efficacy and safety of the selective alpha(1)-blocker alfuzosin in men with lower urinary tract symptoms (LUTS) and painful ejaculation, compared with those with LUTS only, as painful ejaculation is one of the most prevalent, differentiating and bothersome symptoms in men with chronic prostatitis/chronic pelvic pain syndrome." | 5.12 | The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation. ( Elhilali, M; Emberton, M; Nickel, JC; Vallancien, G, 2006) |
| "To examine the efficacy and safety of a once-daily formulation of alfuzosin in a pooled analysis of three parallel, randomized, double-blind, placebo-controlled 3-month studies of patients with lower urinary tract symptoms (LUTS) consistent with clinical benign prostatic hyperplasia." | 5.10 | Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. ( Nordling, J; Roehrborn, CG; Van Kerrebroeck, P, 2003) |
| " Search terms included benign prostatic hyperplasia, alfuzosin, treatment, alpha(1)-adrenergic receptor blocker, long-term, followup, lower urinary tract symptoms, complications or adverse events, sexual, retention and cardiovascular." | 4.83 | Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. ( McVary, KT, 2006) |
| "To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Prostate Symptom Score (IPSS) >8 (range of scores, 0-35), and sexual attempts at least once per month were enrolled." | 3.78 | Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia. ( Chang, HC; Chen, CS; Chen, WH; Chiang, PH; Chu, SH; Hwang, TI; Lee, LM; Lin, MS; Yeh, SD, 2012) |
| "To assess the 3-year efficacy and safety of the selective alpha(1)-blocker alfuzosin at 10 mg once daily in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in 'real-life practice'." | 3.74 | Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ, 2008) |
| " The follow-up included 3 visits: visit of inclusion in the program of patients with a previously prescribed drug of Alfuprost MR in a dosage of 10 mg once a day (visit "0"), visit 1 at 30 days (+/-5 days) later, and visit 2 at 90 days (+/-5 days) after inclusion in the study." | 1.72 | [The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)]. ( Bernikov, AN; Loran, OB; Pushkar, DY, 2022) |
| "Incidence of benign prostatic hyperplasia (BPH), one of the most common conditions affecting adult men, increases dramatically after the age of 50." | 1.42 | [Impact of alfuzosin 10 mg once daily on quality of life in Tunisian patients with lower urinary symptoms suggestive of benign prostatic hyperplasia]. ( Adbi, H; Ben Raies, N; Ben Rhouma, S; Binous, MY; H'sairi, M; Horchani, A; Mosbah, AT; Nouira, Y, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Pushkar, DY | 1 |
| Loran, OB | 1 |
| Bernikov, AN | 1 |
| Pierce, H | 1 |
| Fainberg, J | 1 |
| Gaffney, C | 1 |
| Aboukhashaba, A | 1 |
| Khan, A | 1 |
| Kashanian, J | 1 |
| Liu, S | 1 |
| Yu, Y | 1 |
| Gao, Y | 1 |
| Yang, X | 1 |
| Pang, Z | 1 |
| Ben Rhouma, S | 1 |
| H'sairi, M | 1 |
| Adbi, H | 1 |
| Binous, MY | 1 |
| Nouira, Y | 1 |
| Ben Raies, N | 1 |
| Mosbah, AT | 1 |
| Horchani, A | 1 |
| Kim, MK | 1 |
| Cheon, J | 1 |
| Lee, KS | 1 |
| Chung, MK | 1 |
| Lee, JY | 1 |
| Lee, SW | 1 |
| Kim, SW | 1 |
| Chung, BH | 1 |
| Park, K | 1 |
| Park, JK | 1 |
| Hwang, TI | 1 |
| Chu, SH | 1 |
| Lin, MS | 1 |
| Chen, CS | 1 |
| Lee, LM | 1 |
| Chang, HC | 1 |
| Yeh, SD | 1 |
| Chen, WH | 1 |
| Chiang, PH | 1 |
| Roehrborn, CG | 1 |
| Van Kerrebroeck, P | 1 |
| Nordling, J | 1 |
| van Moorselaar, RJ | 2 |
| Hartung, R | 2 |
| Emberton, M | 3 |
| Harving, N | 2 |
| Matzkin, H | 2 |
| Elhilali, M | 3 |
| Alcaraz, A | 2 |
| Vallancien, G | 3 |
| McVary, KT | 1 |
| Elhilali, MM | 1 |
| Nickel, JC | 1 |
2 reviews available for alfuzosin and Sex Disorders
| Article | Year |
|---|---|
Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
Topics: Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quality of Life; Quinazolines; Se | 2006 |
Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Huma | 2006 |
5 trials available for alfuzosin and Sex Disorders
5 other studies available for alfuzosin and Sex Disorders
| Article | Year |
|---|---|
[The influence of alfuzosin monotherapy on the sexual function of patients with benign prostatic hyperplasia in real clinical practice (results of a Russian multicenter study)].
Topics: Adrenergic alpha-Antagonists; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Qua | 2022 |
Postorgasmic illness syndrome: potential new treatment options for a rare disorder.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Humans; Male; Orgasm; Prazosin; Quinazolines; Sexual | 2020 |
[Impact of alfuzosin 10 mg once daily on quality of life in Tunisian patients with lower urinary symptoms suggestive of benign prostatic hyperplasia].
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Humans; Male; Middle Aged; Prospective Studies; Prost | 2015 |
Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia.
Topics: Aged; Drug Administration Schedule; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male | 2012 |
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Erectile Dysfunction; Humans; Male; Nocturi | 2008 |